Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?

Hasan, Jahidul; Rabbani, Raihan; Anam, Ahmad Mursel; Huq, Shihan Mahmud Redwanul

doi:10.1016/j.jinf.2021.05.011

Cited by 7 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, we read with great interest a recent article by Hasan et al who reported data from a small retrospective cases series of COVID-19 patients that received an IL-17A inhibitor (secukinumab) 3 . The authors demonstrated that this type of therapy, aimed at a new target, could reduce the severity of the cytokine storm and ultimately improve clinical outcomes in patients with severe COVID-19 pneumonia.…”

mentioning

confidence: 99%

N-acetylcysteine for the treatment of COVID-19 among hospitalized patients

Авдеев

Gaynitdinova

Merzhoeva

et al. 2022

Journal of Infection

View full text Add to dashboard Cite

mentioning

confidence: 99%

N-acetylcysteine for the treatment of COVID-19 among hospitalized patients

Авдеев

Gaynitdinova

Merzhoeva

et al. 2022

Journal of Infection

View full text Add to dashboard Cite

“…Astegolimab, which inhibits the IL-33 signalling pathway, has passed phase II trials and shown to be useful in reducing asthma exacerbation rates [44]. IL-17 inhibitor secukinumab reduced CRS severeness in COVID-19 cases in a combined treatment with JAK inhibitor baricitinib [45]. Furthermore, CCR5 blockade using leronlimab also showed improved patients' recoveries in COVID-19-induced CRS cases [46].…”

Section: Anti-gm-csfmentioning

confidence: 99%

Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome

Liu

2024

Third International Conference on Biological Engineering and Medical Science (ICBioMed2023)

View full text Add to dashboard Cite

CAR-T cell therapy is a highly promising therapy, recently developed to treat haematological malignancies. However, many limitations including immunosuppressive microenvironment, cytokine-induced toxicities, neurotoxicity, antigen escape, cell trafficking, and tumour infiltration are still in the way of safely applying this therapy. IL-6 and IL-1 are key players in the cytokine storm, produced by bystander immune cells and CAR-T cells. The secreted cytokines and chemokines can lead to cytokine release syndrome (CRS) and ways to overcome this are being studied. In this review, recent findings on anti-cytokine treatments using monoclonal antibodies or recombinant proteins targeting CAR-T cellinduced cytokine storm will be discussed.

show abstract

“…For example, a retrospective study blocking Th17 T cells with the anti-IL-17 mAb netakimab proved effective and was well tolerated ( 101 ). In addition, a trial in Bangladesh that combined an anti-IL17A mAb with the JAK inhibitor Barictib was effective against COVID-19 respiratory disease, although the therapy was followed by a higher frequency of secondary infections than in controls ( 102 ). Moreover, as discussed in the previous section, mitigation of the severity of COVID-19 lesions has also been achieved using mAbs against some cytokines produced by inflammatory T cells as well as by innate cell types.…”

Section: Minimizing Inflammatory Reactions By Manipulating the Activi...mentioning

confidence: 99%

Controlling viral inflammatory lesions by rebalancing immune response patterns

Mulik,

Berber,

Sehrawat

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

In this review, we discuss a variety of immune modulating approaches that could be used to counteract tissue-damaging viral immunoinflammatory lesions which typify many chronic viral infections. We make the point that in several viral infections the lesions can be largely the result of one or more aspects of the host response mediating the cell and tissue damage rather than the virus itself being directly responsible. However, within the reactive inflammatory lesions along with the pro-inflammatory participants there are also other aspects of the host response that may be acting to constrain the activity of the damaging components and are contributing to resolution. This scenario should provide the prospect of rebalancing the contributions of different host responses and hence diminish or even fully control the virus-induced lesions. We identify several aspects of the host reactions that influence the pattern of immune responsiveness and describe approaches that have been used successfully, mainly in model systems, to modulate the activity of damaging participants and which has led to lesion control. We emphasize examples where such therapies are, or could be, translated for practical use in the clinic to control inflammatory lesions caused by viral infections.

show abstract

Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?

Cited by 7 publications

References 9 publications

N-acetylcysteine for the treatment of COVID-19 among hospitalized patients

N-acetylcysteine for the treatment of COVID-19 among hospitalized patients

Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome

Controlling viral inflammatory lesions by rebalancing immune response patterns

Contact Info

Product

Resources

About